The groundbreaking success of Viagra undeniably reshaped the pharmaceutical landscape, but investing in companies primarily reliant on generic versions presents a complex picture. Despite early earnings were impressive, the cessation of patents and the rise of discounted alternatives have weakened the customer base. Consequently, a thorough evaluat